OBJECTIVE: To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal phase, on intracytoplasmic sperm injection (ICSI) outcome. MATERIALS AND METHODS: One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study. Patients were randomly assigned to receive a single dose of GnRH agonist or placebo. Implantation rate and clinical pregnancy rate were the main outcomes. RESULTS: Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo. CONCLUSION: Luteal phase GnRH agonist administration enhances ICSI clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Razieh et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: